Commonwealth Equity Services, LLC Adma Biologics, Inc. Transaction History

Commonwealth Equity Services, LLC

$66 Billion
Q3 2024

A detailed history of Commonwealth Equity Services, LLC transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 10,564 shares of ADMA stock, worth $169,869. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,564

Previous 15,710 32.76%

Holding current value

$169,869

Previous $176,000 19.89%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$11.21 - $20.03 $57,686 - $103,074	-5,146 Reduced 32.76%	10,564 $211,000
Q2 2024 Jul 31, 2024	BUY	$5.98 - $11.18 $17,641 - $32,981	2,950 Added 23.12%	15,710 $176,000
Q1 2024 Apr 29, 2024	SELL	$4.4 - $6.74 $15,840 - $24,264	-3,600 Reduced 22.0%	12,760 $84,000
Q3 2023 Oct 23, 2023	BUY	$3.47 - $4.61 $21,687 - $28,812	6,250 Added 61.82%	16,360 $59,000
Q1 2023 May 11, 2023	SELL	$3.01 - $3.87 $5,393 - $6,935	-1,792 Reduced 15.06%	10,110 $33,000
Q4 2022 Feb 07, 2023	BUY	$2.47 - $3.88 $4,426 - $6,952	1,792 Added 17.73%	11,902 $46,000
Q3 2022 Nov 14, 2022	BUY	$2.03 - $2.86 $20,523 - $28,914	10,110 New	10,110 $24,000
Q2 2022 Jul 19, 2022	SELL	$1.43 - $2.2 $37,194 - $57,222	-26,010 Closed	0 $0
Q1 2022 May 04, 2022	BUY	$1.28 - $1.83 $3,840 - $5,490	3,000 Added 13.04%	26,010 $47,000
Q4 2021 Jan 31, 2022	SELL	$1.09 - $1.66 $2,180 - $3,320	-2,000 Reduced 8.0%	23,010 $32,000
Q3 2021 Oct 29, 2021	SELL	$1.13 - $1.65 $5,649 - $8,250	-5,000 Reduced 16.66%	25,010 $28,000
Q2 2021 Aug 11, 2021	SELL	$1.51 - $2.07 $30,719 - $42,112	-20,344 Reduced 40.4%	30,010 $48,000
Q1 2021 May 04, 2021	BUY	$1.67 - $2.95 $84,091 - $148,544	50,354 New	50,354 $88,000

Others Institutions Holding ADMA

# of Institutions

312

Shares Held

184M

Call Options Held

917K

Put Options Held

91.6K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.16B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.

Account

Commonwealth Equity Services, LLC Adma Biologics, Inc. Transaction History